Vaginal misoprostol administered at home after mifepristone (RU486) for abortion

Eric A. Schaff, Lisa S. Stadalius, Steven H. Eisinger, Peter Franks

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

BACKGROUND. There have been no US studies published on the effectiveness, safety, time to bleeding, and acceptability of misoprostol administered by vagina at home and repeated, if needed, after mifepristone was administered for abortion in women up to 8 weeks pregnant. METHODS. A prospective trial was conducted with women up to 8 weeks pregnant wanting an abortion. After receiving mifepristone 600 mg orally, subjects self- administered vaginal misoprostol 800 μg at home 2 days later. Subjects returned within 7 days, and if the gestational sac was still present on ultrasound, a repeat dose of misoprostol was administered in the office. Subjects completed a daily symptom log and a questionnaire on the acceptability of the procedures. RESULTS. Of the 166 subjects, 163 (98%) had a complete medical abortion. Three subjects presented with persistent bleeding and an incomplete abortion from 27 to 35 days after taking mifepristone and required surgical intervention. Vaginal spotting or bleeding occurred in 104 (62%) subjects before taking misoprostol, and 18 (11%) did not use misoprostol. Bleeding occurred on average 3.5 hours (SD, 3.2) after taking misoprostol. Six (4%) subjects required a second dose of misoprostol. Gastrointestinal side effects were common, mild, and brief. One hundred fifty-nine (96%) subjects agreed that the procedure went well, and 146 (90%) agreed that home administration of misoprostol was acceptable. CONCLUSIONS. Two days after taking mifepristone, misoprostol administered by vagina was found to be safe, highly effective, and acceptable to women. Since only 6 subjects needed a second dose of misoprostol, conclusions about repeat doses are not possible. This procedure is a promising alternative to surgical abortion.

Original languageEnglish (US)
Pages (from-to)353-360
Number of pages8
JournalJournal of Family Practice
Volume44
Issue number4
StatePublished - Apr 1997
Externally publishedYes

Fingerprint

Misoprostol
Mifepristone
Vagina
Hemorrhage
Incomplete Abortion
Gestational Sac
Metrorrhagia
Bleeding Time
Safety

Keywords

  • Abortion
  • abortion induced
  • mifepristone
  • misoprostol

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. / Schaff, Eric A.; Stadalius, Lisa S.; Eisinger, Steven H.; Franks, Peter.

In: Journal of Family Practice, Vol. 44, No. 4, 04.1997, p. 353-360.

Research output: Contribution to journalArticle

Schaff, EA, Stadalius, LS, Eisinger, SH & Franks, P 1997, 'Vaginal misoprostol administered at home after mifepristone (RU486) for abortion', Journal of Family Practice, vol. 44, no. 4, pp. 353-360.
Schaff, Eric A. ; Stadalius, Lisa S. ; Eisinger, Steven H. ; Franks, Peter. / Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. In: Journal of Family Practice. 1997 ; Vol. 44, No. 4. pp. 353-360.
@article{58870ba75ccd4489b4f1090fdcc9b52d,
title = "Vaginal misoprostol administered at home after mifepristone (RU486) for abortion",
abstract = "BACKGROUND. There have been no US studies published on the effectiveness, safety, time to bleeding, and acceptability of misoprostol administered by vagina at home and repeated, if needed, after mifepristone was administered for abortion in women up to 8 weeks pregnant. METHODS. A prospective trial was conducted with women up to 8 weeks pregnant wanting an abortion. After receiving mifepristone 600 mg orally, subjects self- administered vaginal misoprostol 800 μg at home 2 days later. Subjects returned within 7 days, and if the gestational sac was still present on ultrasound, a repeat dose of misoprostol was administered in the office. Subjects completed a daily symptom log and a questionnaire on the acceptability of the procedures. RESULTS. Of the 166 subjects, 163 (98{\%}) had a complete medical abortion. Three subjects presented with persistent bleeding and an incomplete abortion from 27 to 35 days after taking mifepristone and required surgical intervention. Vaginal spotting or bleeding occurred in 104 (62{\%}) subjects before taking misoprostol, and 18 (11{\%}) did not use misoprostol. Bleeding occurred on average 3.5 hours (SD, 3.2) after taking misoprostol. Six (4{\%}) subjects required a second dose of misoprostol. Gastrointestinal side effects were common, mild, and brief. One hundred fifty-nine (96{\%}) subjects agreed that the procedure went well, and 146 (90{\%}) agreed that home administration of misoprostol was acceptable. CONCLUSIONS. Two days after taking mifepristone, misoprostol administered by vagina was found to be safe, highly effective, and acceptable to women. Since only 6 subjects needed a second dose of misoprostol, conclusions about repeat doses are not possible. This procedure is a promising alternative to surgical abortion.",
keywords = "Abortion, abortion induced, mifepristone, misoprostol",
author = "Schaff, {Eric A.} and Stadalius, {Lisa S.} and Eisinger, {Steven H.} and Peter Franks",
year = "1997",
month = "4",
language = "English (US)",
volume = "44",
pages = "353--360",
journal = "Journal of Family Practice",
issn = "0094-3509",
publisher = "Appleton-Century-Crofts",
number = "4",

}

TY - JOUR

T1 - Vaginal misoprostol administered at home after mifepristone (RU486) for abortion

AU - Schaff, Eric A.

AU - Stadalius, Lisa S.

AU - Eisinger, Steven H.

AU - Franks, Peter

PY - 1997/4

Y1 - 1997/4

N2 - BACKGROUND. There have been no US studies published on the effectiveness, safety, time to bleeding, and acceptability of misoprostol administered by vagina at home and repeated, if needed, after mifepristone was administered for abortion in women up to 8 weeks pregnant. METHODS. A prospective trial was conducted with women up to 8 weeks pregnant wanting an abortion. After receiving mifepristone 600 mg orally, subjects self- administered vaginal misoprostol 800 μg at home 2 days later. Subjects returned within 7 days, and if the gestational sac was still present on ultrasound, a repeat dose of misoprostol was administered in the office. Subjects completed a daily symptom log and a questionnaire on the acceptability of the procedures. RESULTS. Of the 166 subjects, 163 (98%) had a complete medical abortion. Three subjects presented with persistent bleeding and an incomplete abortion from 27 to 35 days after taking mifepristone and required surgical intervention. Vaginal spotting or bleeding occurred in 104 (62%) subjects before taking misoprostol, and 18 (11%) did not use misoprostol. Bleeding occurred on average 3.5 hours (SD, 3.2) after taking misoprostol. Six (4%) subjects required a second dose of misoprostol. Gastrointestinal side effects were common, mild, and brief. One hundred fifty-nine (96%) subjects agreed that the procedure went well, and 146 (90%) agreed that home administration of misoprostol was acceptable. CONCLUSIONS. Two days after taking mifepristone, misoprostol administered by vagina was found to be safe, highly effective, and acceptable to women. Since only 6 subjects needed a second dose of misoprostol, conclusions about repeat doses are not possible. This procedure is a promising alternative to surgical abortion.

AB - BACKGROUND. There have been no US studies published on the effectiveness, safety, time to bleeding, and acceptability of misoprostol administered by vagina at home and repeated, if needed, after mifepristone was administered for abortion in women up to 8 weeks pregnant. METHODS. A prospective trial was conducted with women up to 8 weeks pregnant wanting an abortion. After receiving mifepristone 600 mg orally, subjects self- administered vaginal misoprostol 800 μg at home 2 days later. Subjects returned within 7 days, and if the gestational sac was still present on ultrasound, a repeat dose of misoprostol was administered in the office. Subjects completed a daily symptom log and a questionnaire on the acceptability of the procedures. RESULTS. Of the 166 subjects, 163 (98%) had a complete medical abortion. Three subjects presented with persistent bleeding and an incomplete abortion from 27 to 35 days after taking mifepristone and required surgical intervention. Vaginal spotting or bleeding occurred in 104 (62%) subjects before taking misoprostol, and 18 (11%) did not use misoprostol. Bleeding occurred on average 3.5 hours (SD, 3.2) after taking misoprostol. Six (4%) subjects required a second dose of misoprostol. Gastrointestinal side effects were common, mild, and brief. One hundred fifty-nine (96%) subjects agreed that the procedure went well, and 146 (90%) agreed that home administration of misoprostol was acceptable. CONCLUSIONS. Two days after taking mifepristone, misoprostol administered by vagina was found to be safe, highly effective, and acceptable to women. Since only 6 subjects needed a second dose of misoprostol, conclusions about repeat doses are not possible. This procedure is a promising alternative to surgical abortion.

KW - Abortion

KW - abortion induced

KW - mifepristone

KW - misoprostol

UR - http://www.scopus.com/inward/record.url?scp=0030897554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030897554&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 353

EP - 360

JO - Journal of Family Practice

JF - Journal of Family Practice

SN - 0094-3509

IS - 4

ER -